STOCK TITAN
  1. Home
  2. News
  3. SCLX

Scilex Holding Company - $SCLX STOCK NEWS

Welcome to our dedicated page for Scilex Holding Company news (Ticker: $SCLX), a resource for investors and traders seeking the latest updates and insights on Scilex Holding Company stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Scilex Holding Company's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Scilex Holding Company's position in the market.

News
Scilex Holding Company Announces Closing of $15 Million Registered Direct Offering
Rhea-AI Summary
Scilex Holding Company (Nasdaq: SCLX) has successfully closed a $15 million registered direct offering, consisting of 15,000,000 shares of common stock and warrants. The offering was priced at $1.00 per share, with warrants exercisable at $1.10 per share. The gross proceeds were $15 million before fees. The company plans to use the funds for various purposes, including working capital, research and development, and potential acquisitions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.32%
Tags
offering
-
News
Scilex Holding Company Announces $15 Million Registered Direct Offering
Rhea-AI Summary
Scilex Holding Company, a revenue-generating company focusing on non-opioid pain management products, announces a $15 million registered direct offering. The offering includes the sale of 15,000,000 shares of common stock and warrants at $1.00 per share, with an exercise price of $1.10 per share. Rodman & Renshaw is the exclusive placement agent.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13%
Tags
offering
-
News
Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross and Net Sales for ZTlido® for the First Quarter 2024; Implements Planned 2024 Commercial Ramp for Additional Opioid Sparing Product and Reduction of R&D and Other Administrative Expenses
Rhea-AI Summary
Scilex Holding Company reported strong preliminary unaudited financial results for ZTlido® in the first quarter of 2024, with gross sales between $34.0 million to $38.0 million and net sales between $12.0 million to $13.0 million, showing significant growth compared to the same period in 2023. The company also announced plans to reduce R&D and administrative expenses in 2024 while focusing on expanding commercial activities and product production.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.38%
Tags
earnings
News
Scilex Holding Company Announces Launching of Co-Pay Programs for Both ZTlido® and ELYXYB® for Commercially Insured Patients and the addition of ELYXYB® to a Multi-State Medicaid Pharmaceutical Purchasing Group to Its Purchasing Pool
Rhea-AI Summary
Scilex Holding Company launches co-pay programs for ZTlido® and ELYXYB® for commercially insured patients, with out-of-pocket costs capped at $25 monthly. Multi-State Medicaid Pharmaceutical Purchasing Group adds ELYXYB® to its purchasing pool. Scilex aims to improve patient affordability and access to non-opioid pain management products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.16%
Tags
none
-
News
Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend
Rhea-AI Summary
Scilex Holding Company (SCLX) announced the extension of the lock-up period for the shares of common stock previously distributed by Sorrento Therapeutics, Inc. The Court approved the extension to September 30, 2024, or until certain claims are resolved. This extension prohibits the sale, transfer, or disposal of the Dividend Stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.62%
Tags
dividends
-
News
Scilex Holding Company Announces New Out-of-Pocket Costs for Commercially Insured Patients
Rhea-AI Summary
Scilex Holding Company (SCLX) announces capped out-of-pocket costs for its pain management products for commercially insured patients, with some eligible patients paying as low as $0. The company is focused on providing affordable non-opioid solutions, resolving issues with co-pay savings card processing, and launching a new product in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.94%
Tags
none
News
Scilex Holding Company Announces Seeking Approval from the FDA for Modification of the Gloperba® Label to Provide Specific Dosing Guidance for Patients with Renal Impairment and Other Circumstances Where Dose Adjustment is Needed
Rhea-AI Summary
Scilex Holding Company (SCLX) seeks FDA approval to modify Gloperba® label for dosing flexibility, targeting gout patients with renal impairment. The market potential is significant with increasing gout cases and unmet needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.74%
Tags
none
-
News
Scilex Holding Company Announces a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex’s Filing of a sNDA with the FDA Seeking to Expand the Label for its FDA-Approved Liquid Colchicine Product, Gloperba®
Rhea-AI Summary
Scilex Holding Company (SCLX) settles patent infringement lawsuit with Takeda Pharmaceuticals, granting non-exclusive license to certain patents. The terms of the agreements are confidential and subject to approval by relevant authorities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.74%
Tags
none
-
News
Scilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation
Rhea-AI Summary
Scilex Holding Company (SCLX) announced paying off $1.3 million in convertible debentures and $15 million in a promissory note, signaling financial strength and readiness for growth. The company aims to develop non-opioid pain management products, expand commercialization efforts, and address the opioid crisis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.46%
Tags
none
News
Scilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB® Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in Canada
Rhea-AI Summary
Scilex Holding Company (Nasdaq: SCLX) announces progress in obtaining approval for ELYXYB®, a first-line treatment for migraine, in Canada. The market potential is significant, with a focus on fast and safe alternatives for acute migraine patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock SCLX logo
Scilex Holding Company

Nasdaq:SCLX

SCLX Rankings

#4217 Ranked by Market Cap
#5355 Ranked by Stock Gains
N/A Ranked by Dividends

SCLX Stock Data

111.10M
43.43M
37.7%
16%
6.2%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States of America
PALO ALTO